VERAXA Biotech AG (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
The findings further validate the potential of the BiTAC-ADC platform and complement VERAXA's BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. For more details, the full press release is available at https://ibn.fm/QiPhH.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
This proof-of-concept data marks a significant step for VERAXA, as it demonstrates the potential of its BiTAC-ADC platform to address key challenges in oncology, such as off-target toxicity and limited therapeutic window. By enabling tumor-restricted activation, the platform could enhance the efficacy of cancer treatments while reducing side effects, offering hope for patients with solid tumors that are difficult to treat. The company's ability to present two distinct platforms positions it favorably for strategic partnerships at the upcoming BIO International Convention.
Investors can find the latest news and updates relating to VRXA in the company’s newsroom at http://ibn.fm/VRXA.
